Capital World Investors Lowers Holdings in argenex SE $ARGX

Capital World Investors decreased its stake in shares of argenex SE (NASDAQ:ARGX) by 2.2% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,916,234 shares of the company’s stock after selling 43,270 shares during the quarter. Capital World Investors’ holdings in argenex were worth $1,611,433,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Havemeyer Place LP purchased a new position in argenex during the fourth quarter valued at $399,000. Pinebridge Investments LLC purchased a new position in argenex during the fourth quarter valued at $60,582,000. Vise Technologies Inc. raised its stake in argenex by 26.8% during the fourth quarter. Vise Technologies Inc. now owns 620 shares of the company’s stock valued at $522,000 after buying an additional 131 shares during the last quarter. Daiwa Securities Group Inc. raised its stake in argenex by 1.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 1,681 shares of the company’s stock valued at $1,413,000 after buying an additional 25 shares during the last quarter. Finally, Shepherd Street Advisors LLC purchased a new position in argenex during the fourth quarter valued at $1,213,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Price Performance

ARGX stock opened at $891.32 on Friday. argenex SE has a 1-year low of $510.05 and a 1-year high of $934.62. The business has a fifty day moving average price of $794.90 and a 200-day moving average price of $813.42. The stock has a market capitalization of $55.43 billion, a P/E ratio of 39.68, a P/E/G ratio of 1.36 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a return on equity of 33.28% and a net margin of 31.31%.The company had revenue of $1.31 billion during the quarter. As a group, analysts anticipate that argenex SE will post 26.25 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Zacks Research upgraded argenex from a “strong sell” rating to a “hold” rating in a research note on Friday, February 20th. Glj Research upgraded argenex to a “strong-buy” rating in a research note on Friday, April 3rd. Wedbush restated an “outperform” rating and issued a $1,000.00 price target on shares of argenex in a research note on Thursday. Deutsche Bank Aktiengesellschaft upgraded argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Royal Bank Of Canada decreased their price target on argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a research note on Friday, February 27th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,019.50.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.